CoChat

Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus

Diabetes Prevention Trial–Type 1 Diabetes Study Group · 2002 · New England Journal of Medicine

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa012350

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Research works printed but not linked: 1

  1. 10.1210/jc.75.6.1574 · DOI

Cited by

See all 836

Metadata

Authors
Diabetes Prevention Trial–Type 1 Diabetes Study Group
Affiliations
University of Miami (US)
Corresponding author
Diabetes Prevention Trial–Type 1 Diabetes Study Group
Venue
New England Journal of Medicine
Published
2002-05-30
Volume
346
Issue
22
Pages
1685-1691
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W614574849
Cited by
836
References
30
Citations by year
2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
FWCI
28.81
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
MeSH terms
Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.